And don't forget Menarini whom Angle are targeting. They have the drug Orserdu.https://www.menarini.com/en-us/news/news-detail/european-commission-approves-menarini-groups-orserdu174-elacestrant-for-the-treatment-of-patients-with-er-her2-locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation |
Interview now out. Illumina are very excited... |
'The two companies plan to collaborate further, aiming to refine liquid biopsy techniques for more effective cancer monitoring.
"We are excited at the prospect of combining ANGLE's Parsortix system with Illumina's NGS assays and optimising a workflow that will enable Illumina customers to offer CTC analysis in the future," said Karen Miller, ANGLE's chief scientific officer.++ |
A little competition is a good thing. I strongly suspect Illumina isn't the only interested party. |
timbo003 - 🤞 not yet.
"Illumina has completed 17 acquisitions with an average acquisition amount of $1.33B. Its most active year was 2013, with 4 acquisitions, and it has averaged nearly 1 acquisition per year over the past three years, including 1 in 2024 so far.4 Oct 2024" |
timbo, did any of those Companies present in ILMN's slot at EACR before being taken over ? might be stretching the research prowess |
.......
Who is next?
....... |
This is very similar to exciting news 12 months ago.
It messed around the 15p level for the morning then started moving sharply in the afternoon and by the next morning it spiked to 37p high I remember it well.
Too many jittery day traders cutting their own throats here panic selling when it starts to fall, easy pray for the mm's, they usually end up buying back in higher later on |
However the bears try to spin it $20bn Companies do not give away 'their' slots at major Conferences to outside Companies unless those Companies and their complementary tech ADDS VALUE to their own product/service offering. So a $20bn Company like Illumina having £40m Angle at a major Industry event is v.significant.
You'd have to imagine there are parallel strategic partnership agreement discussion going on in background too and probably already quite well advanced. A Strategic Investment at a premium would light a fire under AGL as it would address the Bears familiar crutch re funding.
I suspect we will really get going this afternoon when the US Investors / Illumina followers wake up |
I don’t think the market gets it.
This is a clear indication that this may become the ‘premium’; liquid biopsy analysis. You can run a standard ctDNA but why not cough up the extra £2.5k for the full analysis which will tell you which drugs (at a cost of £5-10k per month) are most likely to work.
There’s a debate about about funding… It’s all nonsense if Allumina are truly on board. They’ll just take a small stake or buy the whole company for £200m or so, small change for them. |
gooosed,
Excellent RNS and well spotted by gooosed last Friday. Will post again the link in his 27067:- |
Launch your other aliases too while you're at it |
Didnt you tell everyone to sell at 7.5p recently? LMAO |
Suspect some of the members/sponsors of the EACR may take more than a passing interest in the webinar... |
Try harder Muppets it's not exactly flying is it . Amateurs as usual desperately trying to ramp it after years of failure .
This is a long time off generating money for agl and they have to get there first hence the lack of big rise oh dear sliding back I wonder why |
Breakout on the 1 year chart now. 24p next stop.Then 40p targetPs better chartist (I'm not that good) please post the charts if you can |
Pipe down Martyn |
Excellent and highlighted here last week. Significant. Very significant. |
Some desperate for this to rise but it's not money now it's more jam later down the road and that's why it's not moving a lot . Fund raise coming will gold it back and a long wait before any money hits afla accounts from this |
IF Jan 2024 is the middle of a W double bottom the chart symmetry would suggest potential target prices of 50p and 150p in the next few weeks / months ? |
AGL Mkt Cap £40m
ILMN Mkt Cap $20,000m
If Illumina are giving over the whole of their EACR slot to Angle what does that say about the scientific and commercial significance and potential ?! |
tasty volume...
getting my senses mixed up. |
"Illumina is the world's largest provider of NGS systems and assays and has built an installed base of more than 23,000 sequencing systems across more than 9,500 customers in 155 countries." Borrowed from elsewhere.
As mentioned in a previous post the evidence of Angle forging closer ties is out there. A smart move by Illumina as this webinar serves as a signalling & advertising for things to come. ie Perhaps a pre-cursor to a commercial tie up coming. |
Can Andrew get Trump to mention this on X?
Great news from a significant player in the field. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
